<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.</PublisherName>
				<JournalTitle>Asian Pacific Journal of Cancer Prevention</JournalTitle>
				<Issn>1513-7368</Issn>
				<Volume>15</Volume>
				<Issue>21</Issue>
				<PubDate PubStatus="epublish">
					<Year>2014</Year>
					<Month>12</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Comprehensive Assessment of Associations between ERCC2 Lys751Gln/Asp312Asn Polymorphisms and Risk of Non-Hodgkin Lymphoma</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>9347</FirstPage>
			<LastPage>9353</LastPage>
			<ELocationID EIdType="pii">30076</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>1970</Year>
					<Month>01</Month>
					<Day>01</Day>
				</PubDate>
			</History>
		<Abstract>&lt;b&gt;Background:&lt;/b&gt; Excision repair crossing-complementing group 2 (ERCC2), also called xeroderma pigmentosumcomplementary group D (XPD), plays a crucial role in the nucleotide excision repair (NER) pathway. Previousepidemiological studies have reported associations between ERCC2 polymorphisms and non-Hodgkin lymphoma(NHL) risk, but the results have remained controversial. Materials and &lt;br/&gt;&lt;b&gt;Methods&lt;/b&gt;: We conducted this metaanalysisbased on eligible case-control studies to investigate the role of two ERCC2 polymorphisms (Lys751Glnand Asp312Asn) in determining susceptibility to NHL. Ten case-control studies from several electronic databaseswere included in our study up to August 14, 2014. Pooled odds ratios (ORs) and 95% confidence intervals (CIs)were calculated using fixed- or random-effects models to estimate the association strength. &lt;br/&gt;&lt;b&gt;Results&lt;/b&gt;: The combinedresults based on all studies did not show any association between Lys751Gln/Asp312Asn polymorphisms and NHLrisk for all genetic models. Stratified analyses by histological subtype and ethnicity did not indicate any significantassociation between Lys751Gln polymorphism and NHL risk. However, a significant reduced risk of NHL wasfound among population-based studies (Lys/Gln versus Lys/Lys: OR=0.87, 95% CI=0.77-0.99, P=0.037) but nothospital-based studies. As for Asp312Asn polymorphism, there was no evidence for the association between thispolymorphism and the risk of NHL in all subgroup analyses. &lt;br/&gt;&lt;b&gt;Conclusions&lt;/b&gt;: This meta-analysis suggests that theremay be no association between Lys751Gln/Asp312Asn polymorphism and the risk of NHL and its two subtypes,whereas ERCC2 Lys751Gln heterozygote genotype may provide protective effects against the risk of NHL inpopulation-based studies. Therefore, large-scale and well-designed studies are needed to clarify the effects ofhaplotypes, gene-gene, and gene-environment interactions on these polymorphisms and the risk of NHL and itsdifferent histological subtypes in an ethnicity specific population.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">ERCC2</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">XPD</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Polymorphism</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Non-Hodgkin lymphoma</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Meta-analysis</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://journal.waocp.org/article_30076_2376378b7471bc2063a074b199a4c15a.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
